JP2023529908A5 - - Google Patents
Info
- Publication number
- JP2023529908A5 JP2023529908A5 JP2022575824A JP2022575824A JP2023529908A5 JP 2023529908 A5 JP2023529908 A5 JP 2023529908A5 JP 2022575824 A JP2022575824 A JP 2022575824A JP 2022575824 A JP2022575824 A JP 2022575824A JP 2023529908 A5 JP2023529908 A5 JP 2023529908A5
- Authority
- JP
- Japan
- Prior art keywords
- pyrazino
- pyrrolidine
- ethyl
- optionally substituted
- hydroxyphenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063036811P | 2020-06-09 | 2020-06-09 | |
| US63/036,811 | 2020-06-09 | ||
| PCT/US2021/036664 WO2021252666A1 (en) | 2020-06-09 | 2021-06-09 | Brm targeting compounds and associated methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023529908A JP2023529908A (ja) | 2023-07-12 |
| JP2023529908A5 true JP2023529908A5 (enExample) | 2024-06-18 |
Family
ID=76731093
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022575824A Pending JP2023529908A (ja) | 2020-06-09 | 2021-06-09 | Ｂｒｍ標的化化合物及び関連する使用方法 |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US11702423B2 (enExample) |
| EP (2) | EP4161935B1 (enExample) |
| JP (1) | JP2023529908A (enExample) |
| KR (1) | KR20230037549A (enExample) |
| CN (1) | CN115867554B (enExample) |
| AU (1) | AU2021289730A1 (enExample) |
| BR (1) | BR112022025061A2 (enExample) |
| CA (1) | CA3185888A1 (enExample) |
| DK (1) | DK4161935T3 (enExample) |
| ES (1) | ES3034380T3 (enExample) |
| FI (1) | FI4161935T3 (enExample) |
| IL (1) | IL298933B2 (enExample) |
| MX (1) | MX2022015732A (enExample) |
| PL (1) | PL4161935T3 (enExample) |
| PT (1) | PT4161935T (enExample) |
| WO (1) | WO2021252666A1 (enExample) |
| ZA (1) | ZA202213711B (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3737666A4 (en) | 2018-01-12 | 2022-01-05 | Kymera Therapeutics, Inc. | PROTEIN DEGRADATION AGENTS AND ASSOCIATED USES |
| US12454520B2 (en) | 2018-07-06 | 2025-10-28 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| US12624044B2 (en) | 2019-06-10 | 2026-05-12 | Kymera Therapeutics, Inc. | SMARCA degraders and uses thereof |
| WO2020251972A1 (en) | 2019-06-10 | 2020-12-17 | Kymera Therapeutics, Inc. | Smarca degraders and uses thereof |
| US11679109B2 (en) | 2019-12-23 | 2023-06-20 | Kymera Therapeutics, Inc. | SMARCA degraders and uses thereof |
| WO2021133917A1 (en) | 2019-12-23 | 2021-07-01 | Kymera Therapeutics, Inc. | Smarca inhibitors and uses thereof |
| WO2022099117A1 (en) * | 2020-11-06 | 2022-05-12 | Prelude Therapeutics Incorporated | Brm targeting compounds and associated methods of use |
| US12606568B2 (en) | 2020-12-09 | 2026-04-21 | Kymera Therapeutics, Inc. | SMARCA degraders and uses thereof |
| WO2023278402A1 (en) * | 2021-06-28 | 2023-01-05 | Kymera Therapeutics, Inc. | Smarca degraders and uses thereof |
| JP2024533990A (ja) * | 2021-08-09 | 2024-09-18 | ジェネンテック， インコーポレイテッド | Ｂｒｍの調節に使用するためのフェノール誘導体 |
| AU2023270000A1 (en) * | 2022-05-10 | 2024-11-28 | Foghorn Therapeutics Inc. | Pyrazine derivatives and uses thereof |
| JP2025521091A (ja) * | 2022-05-10 | 2025-07-08 | プレリュード・セラピューティクス・インコーポレイテッド | がんの治療のためのｓｍａｒｃａ４タンパク質分解因子としての６，６ａ，７，８，９，１０－ヘキサヒドロ－５ｈ－ピラジノ［１’，２’：４，５］ピラジノ［２，３－ｃ］ピリダジン誘導体 |
| WO2024064316A1 (en) * | 2022-09-23 | 2024-03-28 | Regents Of The University Of Michigan | Compounds and compositions as smarca2/4 inhibitors and uses thereof |
| WO2024064328A1 (en) * | 2022-09-23 | 2024-03-28 | Regents Of The University Of Michigan | Compounds and compositions as smarca2/4 degraders and uses thereof |
| AU2023356925A1 (en) * | 2022-10-03 | 2025-04-24 | Prelude Therapeutics Incorporated | Improved treatment of cancers using combinations of SMARCA2 degraders and KRAS targeting therapies |
| EP4695250A1 (en) | 2023-04-12 | 2026-02-18 | Aurigene Oncology Limited | Tetracyclic compounds as smarca2 and/or smarca4 degraders |
| WO2025076351A1 (en) | 2023-10-04 | 2025-04-10 | Prelude Therapeutics Incorporated | Combination treatment regimens - smarca2 degrader with gemcitabine |
| US20250114354A1 (en) | 2023-10-04 | 2025-04-10 | Prelude Therapeutics Incorporated | Combination treatment regimens - smarca2 degrader with pd-1 inhibitors |
| US20260115189A1 (en) | 2023-10-04 | 2026-04-30 | Prelude Therapeutics Incorporated | Combination Treatment Regimens - SMARCA2 Degrader With Taxane Anticancer Agent |
| WO2025106482A1 (en) * | 2023-11-13 | 2025-05-22 | Oncopia Therapeutics, Inc. D/B/A Sk Life Science Labs | Compounds and compositions as smarca2/4 degraders and uses thereof |
| WO2025193454A1 (en) | 2024-03-01 | 2025-09-18 | Prelude Therapeutics Incorporated | Brm and brg1 targeting antibody-drug conjugates and methods of use thereof |
| WO2026039756A1 (en) * | 2024-08-16 | 2026-02-19 | Prelude Therapeutics Incorporated | Methods of treating cancer using a smarca2 degrader |
| WO2026090411A1 (en) * | 2024-10-23 | 2026-04-30 | Prelude Therapeutics Incorporated | Brm and brg1 targeting compounds and associated methods of use |
| CN119638700B (zh) * | 2024-11-01 | 2025-11-14 | 中科中山药物创新研究院 | 一种nsd2降解剂及其应用 |
| WO2026152359A1 (en) * | 2025-01-17 | 2026-07-23 | Prelude Therapeutics Incorporated | Polymorphic compounds and uses thereof |
| WO2026156670A1 (en) | 2025-01-24 | 2026-07-30 | Prelude Therapeutics Incorporated | Processes for making smarca2 degraders |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3657744A (en) | 1970-05-08 | 1972-04-25 | Univ Minnesota | Method for fixing prosthetic implants in a living body |
| US4733665C2 (en) | 1985-11-07 | 2002-01-29 | Expandable Grafts Partnership | Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US5350395A (en) | 1986-04-15 | 1994-09-27 | Yock Paul G | Angioplasty apparatus facilitating rapid exchanges |
| US5061273A (en) | 1989-06-01 | 1991-10-29 | Yock Paul G | Angioplasty apparatus facilitating rapid exchanges |
| US5040548A (en) | 1989-06-01 | 1991-08-20 | Yock Paul G | Angioplasty mehtod |
| US4748982A (en) | 1987-01-06 | 1988-06-07 | Advanced Cardiovascular Systems, Inc. | Reinforced balloon dilatation catheter with slitted exchange sleeve and method |
| US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
| CA1322628C (en) | 1988-10-04 | 1993-10-05 | Richard A. Schatz | Expandable intraluminal graft |
| US6344053B1 (en) | 1993-12-22 | 2002-02-05 | Medtronic Ave, Inc. | Endovascular support device and method |
| US5674278A (en) | 1989-08-24 | 1997-10-07 | Arterial Vascular Engineering, Inc. | Endovascular support device |
| US5292331A (en) | 1989-08-24 | 1994-03-08 | Applied Vascular Engineering, Inc. | Endovascular support device |
| MA41598A (fr) * | 2015-02-25 | 2018-01-02 | Constellation Pharmaceuticals Inc | Composés thérapeutiques de pyridazine et leurs utilisations |
| GB2554071A (en) | 2016-09-14 | 2018-03-28 | Univ Dundee | Small molecules |
| IL325835A (en) | 2016-12-23 | 2026-03-01 | Univ Yale | Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides |
| IL300417A (en) | 2017-01-26 | 2023-04-01 | Arvinas Operations Inc | Bifunctional benzothiophene compounds, preparations containing them and their use in therapy |
| WO2019084026A1 (en) | 2017-10-24 | 2019-05-02 | Genentech, Inc. | (4-HYDROXYPYRROLIDIN-2-YL) -HETEROCYCLIC COMPOUNDS AND METHODS OF USE |
| WO2019084030A1 (en) | 2017-10-24 | 2019-05-02 | Genentech, Inc. | (4-HYDROXYPYRROLIDIN-2-YL) -HYDROXAMATE COMPOUNDS AND METHODS OF USE |
| AU2019249849C1 (en) | 2018-04-01 | 2022-09-29 | Arvinas Operations, Inc. | BRM targeting compounds and associated methods of use |
| US12539292B2 (en) | 2018-04-01 | 2026-02-03 | Arvinas Operations, Inc. | BRM targeting compounds and associated methods of use |
| US20220324880A1 (en) | 2019-06-10 | 2022-10-13 | Kymara Therapeutics, Inc. | Smarca inhibitors and uses thereof |
| US20230087825A1 (en) | 2019-06-10 | 2023-03-23 | Kymera Therapeutics, Inc. | Smarca degraders and uses thereof |
| WO2020251972A1 (en) | 2019-06-10 | 2020-12-17 | Kymera Therapeutics, Inc. | Smarca degraders and uses thereof |
| US12624044B2 (en) | 2019-06-10 | 2026-05-12 | Kymera Therapeutics, Inc. | SMARCA degraders and uses thereof |
| WO2021133917A1 (en) * | 2019-12-23 | 2021-07-01 | Kymera Therapeutics, Inc. | Smarca inhibitors and uses thereof |
| US11679109B2 (en) * | 2019-12-23 | 2023-06-20 | Kymera Therapeutics, Inc. | SMARCA degraders and uses thereof |
| WO2022099117A1 (en) * | 2020-11-06 | 2022-05-12 | Prelude Therapeutics Incorporated | Brm targeting compounds and associated methods of use |
-
2021
- 2021-06-09 PT PT217368901T patent/PT4161935T/pt unknown
- 2021-06-09 WO PCT/US2021/036664 patent/WO2021252666A1/en not_active Ceased
- 2021-06-09 CN CN202180049461.6A patent/CN115867554B/zh active Active
- 2021-06-09 BR BR112022025061A patent/BR112022025061A2/pt unknown
- 2021-06-09 PL PL21736890.1T patent/PL4161935T3/pl unknown
- 2021-06-09 CA CA3185888A patent/CA3185888A1/en active Pending
- 2021-06-09 EP EP21736890.1A patent/EP4161935B1/en active Active
- 2021-06-09 EP EP25173100.6A patent/EP4570319A3/en active Pending
- 2021-06-09 FI FIEP21736890.1T patent/FI4161935T3/fi active
- 2021-06-09 ES ES21736890T patent/ES3034380T3/es active Active
- 2021-06-09 MX MX2022015732A patent/MX2022015732A/es unknown
- 2021-06-09 US US17/343,341 patent/US11702423B2/en active Active
- 2021-06-09 DK DK21736890.1T patent/DK4161935T3/da active
- 2021-06-09 JP JP2022575824A patent/JP2023529908A/ja active Pending
- 2021-06-09 KR KR1020237000892A patent/KR20230037549A/ko active Pending
- 2021-06-09 AU AU2021289730A patent/AU2021289730A1/en active Pending
-
2022
- 2022-12-08 IL IL298933A patent/IL298933B2/en unknown
- 2022-12-19 ZA ZA2022/13711A patent/ZA202213711B/en unknown
-
2023
- 2023-05-15 US US18/317,352 patent/US20240018158A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN115397821B (zh) | 含有与bcl6靶向部分连接的e3泛素连接酶结合部分的双官能分子 | |
| JP7644139B2 (ja) | インダゾール系化合物及び関連使用方法 | |
| JP2023501253A5 (enExample) | ||
| JP5261575B2 (ja) | 化学化合物 | |
| CN116789674B (zh) | Nlrp3炎性小体抑制剂 | |
| KR102773702B1 (ko) | Egfr 돌연변이 암의 억제용 화합물 및 이들의 의약 용도 | |
| KR102122244B1 (ko) | 설파모일-아릴아미드 및 b형 간염 치료제로서의 그 용도 | |
| JP6559325B2 (ja) | ヒストン脱アセチル化酵素６阻害剤としての１，３，４−オキサジアゾールアミド誘導体化合物及びこれを含有する薬剤学的組成物， | |
| FI4161935T3 (fi) | Brm:ään kohdennettuja yhdisteitä ja niihin liittyviä käyttömenetelmiä | |
| JP2024528949A (ja) | Ｓｈｐ２タンパク質分解活性を有する化合物及びその医薬用途 | |
| DK2609091T3 (en) | Pharmaceutically active compounds as AXL inhibitors | |
| JP2008528467A5 (enExample) | ||
| JP2025521091A5 (ja) | Ｂｒｍを標的とする化合物および関連する使用方法 | |
| JP2020506922A (ja) | セレブロンリガンド、およびセレブロンリガンドを含有する二官能性化合物 | |
| IL291590B2 (en) | Novel substituted quinoline-8-carbonitrile derivatives having androgen receptor degradation activity and uses thereof | |
| JP2014506599A5 (enExample) | ||
| JP2021107456A (ja) | インドリノン化合物の使用 | |
| JP2020505457A (ja) | ２−アリールスルホンアミド−Ｎ−アリールアセトアミド誘導体化Ｓｔａｔ３ | |
| JP2022522312A (ja) | ピロール化合物 | |
| JP2026500955A (ja) | Ｂｃｌ６タンパク質分解の調節因子、および関連する使用方法 | |
| JP2022500428A5 (enExample) | ||
| JP2025507088A (ja) | キノリン化合物の新規用途 | |
| RU2845145C1 (ru) | Соединения для подавления рака с мутацией egfr и их фармацевтическое применение | |
| RU2848218C2 (ru) | Новое применение хинолинового соединения | |
| JP2024541480A (ja) | Ｂｒｍ標的化化合物及び関連使用方法 |